Miller-fisher Syndrome After COVID-19: Neurochemical Markers As An Early Sign Of Nervous System Involvement
EUROPEAN JOURNAL OF NEUROLOGY
Senel M, Abu-Rumeileh S, Michel D, Garibashvili T, Althaus K, Kassubek J and Otto M.
Eur J Neurol. 2020 Aug 11;10.1111/ene.14473
The Miller Fisher syndrome (MFS) is classified as a variant of the Guillain–Barré syndrome (GBS), accounting for 5‐25% of all GBS cases. Since the coronavirus disease‐2019 (COVID‐19) outbreak, increasing evidence of the neurologic manifestations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, affecting both central and peripheral nervous system, has been described. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical parameters of a case with a typical clinical presentation of MFS after being tested positive for SARS‐CoV‐2 infection.
Share this page